English 中文

About Decheng Capital

Decheng Capital is a leading China healthcare investment firm that provides capital to early and growth stage life science companies. We are a team of investment professionals with complementary expertise, a long history of working together and a shared dedication to building highly successful companies that span the full spectrum of the life sciences industry. Our domain knowledge, access to innovative technologies and ability to bring proven Western products to China make us the preferred partner for entrepreneurs, domestic and multinational companies, government agencies and investors. Decheng Capital is poised to capitalize on a historic opportunity in China’s rapidly developing life sciences industry and to deliver superior returns for our investors.



July 2, 2014
GeneWeave Attracts $12 Million to Provide Same-Shift Sample-In/Susceptibility-Out Diagnostic Solutions for Multi-Drug-Resistant Organisms

March 6, 2014
Mr. Robert King, Decheng’s Co-Anchor LP, Received the 2014 Arbuckle Award

February 14, 2014
GenapSys Featured on Forbes

November 14, 2013
GenapSys Raises $37M to Commercialize Next Generation Sequencing Platform

June 6, 2013
Decheng Capital Celebrates the Final Closing of USD Fund I

February 28, 2012
GeneWeave Biosciences Inks $12M

Copyright © 2011 Decheng Capital LLC. All Rights Reserved.